Tag : Q4

Latest News

ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019

Newsemia
ZURICH & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Regulatory News: ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced...
Latest News

MainStem, Inc. Continues Expansion in the Ancillary Cannabis Supply Industry and Prepares for Merida-Led Series C Round in Q4

Newsemia
SEATTLE–(BUSINESS WIRE)–#CBTmag–MainStem, Inc., a privately funded e-commerce marketplace of ancillary products in the regulated cannabis industry, continues its expansion with revenue increases of approximately 30%...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy